What you should know:
1. Researchers tested BT-11 in 70 patients as either a single-ascending dose or as a seven-day multiple-ascending dose.
2. Fecal concentrations of BT-11 were 6,000 times higher than maximum plasma concentrations. Researchers said the increased concentrations mirrored what they observed in preclinical animal tests.
3. Landos will explore the seven-day, 14 milligram dosage in a phase 2 clinical trial.
More articles on gastroenterology:
3 things to know about outpatient cervical disc replacement
10 things to know about spine surgery for ASCs in 2019
Outpatient revision minimally invasive lumbar decompression: 4 notes on ASC vs. HOPD
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
